Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith K. Singh, Ravi Amrit Madan, James L. Gulley · Clinical Investigation · 2013
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2013
Abstract
Immunotherapy has been recognized as a viable therapeutic approach since the regulatory approval of the autologous cell-based vaccine sipuleucel-T in 2010. Emerging preclinical evidence and early-stage clinical studies point to a potential synergy between currently available immunotherapeutic agents and standard anticancer therapies such as radiation and chemotherapy. Several other immunotherapeutic platforms, such as immune checkpoint inhibitors and DNA- and peptide-based vaccines are also in development and clinical testing. Based on the logistics of their production, these platforms are broadly categorized as patient-specific or off-the-shelf.
Together, they are beginning to transform the therapeutic landscape in prostate cancer. This article reviews the rationale behind immunotherapeutic approaches in castration-resistant prostate cancer, plus the latest available clinical data.
Open the resolved locator · 10.4155/cli.13.46
Metadata licence: OpenAlex metadata (CC0)